Carbon Appoints Ellen Kullman President and CEO, Dr. Joseph DeSimone Named Executive Chairman
21.11.2019 21:02:00 EET | Business Wire | Press release
Carbon (www.carbon3d.com), the world’s leading digital manufacturing platform, announced today that Ellen J. Kullman, former Chairman and CEO of DuPont, has been named President and CEO of the company and Dr. Joseph M. DeSimone has been named Executive Chairman of the Board, effective immediately. Kullman will also remain on Carbon’s board of directors where she has served since 2016. Today’s leadership announcements are the result of a succession plan that DeSimone, Kullman, and members of the board have worked on to prepare the company for its next chapter.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191121005835/en/
Carbon Appoints Ellen Kullman President and CEO, Dr. Joseph DeSimone Named Executive Chairman (Photo: Business Wire)
Carbon has been strengthening its leadership bench over the past several months to support the growth of the business. As President and CEO, Kullman will lead the development and execution of short- and long-term strategies, positioning Carbon to continue delivering value to its employees, customers, partners, and shareholders around the world. DeSimone is transitioning into the role of Executive Chairman to focus on growing mainstream adoption of the Carbon Digital Manufacturing Platform and evangelizing the company’s vision to existing and prospective customers, partners, and the public.
“Today’s announcement is a great honor,” said Kullman. “I am privileged to have spent the last few years on the Carbon board working alongside Joe, one of the greatest entrepreneurs and scientists of our time. Joe has built Carbon into the world’s leading digital manufacturing platform, and as President and CEO of Carbon, I am excited to partner with Joe and build on the solid foundations he’s put into place.”
“For the last six years, I have led Carbon as Chief Executive Officer and am enormously proud of what we’ve accomplished during my tenure,” said DeSimone. “I know what we will accomplish under Ellen will be even more extraordinary. Ellen is the right person to lead Carbon today. She has broad experience across multiple businesses, cycles, and geographies. Her vision, outstanding leadership traits, and distinguished track record will continue to drive Carbon’s growth into the future. In assuming the Executive Chairman role, I will be able to focus on evangelizing the platform and driving adoption more widely.”
Prior to joining DuPont in 1988, Kullman worked for Westinghouse and General Electric. DuPont's board of directors elected Kullman President and a director of the company in October 2008 and Chief Executive Officer in January 2009. She was the nineteenth executive and the first woman to lead the company in its 212-year history. As a business leader, Kullman led double-digit growth of the company’s Safety and Protection business portfolio and started two successful high-growth businesses known today as DuPont Industrial Biosciences and DuPont Sustainable Solutions. During her seven years as CEO, Kullman led the company’s focus on growth in emerging international markets and championed the power of DuPont science and global market knowledge to transform industries. She executed a strong plan and decisively positioned the company for its next generation of growth.
Kullman is co-chair of the Paradigm for Parity coalition and a board director of United Technologies, Dell Technologies, Amgen, and Goldman Sachs. She is a member of the U.S. National Academy of Engineering and past president of the U.S. China Business Council. She serves on the board of trustees of Northwestern University. Kullman has been named one of the “50 Most Powerful Women in Business” by Fortune and one of the “World’s Most Powerful Women” by Forbes. She holds a B.S. in Mechanical Engineering from Tufts University and an MBA from the Kellogg School of Management of Northwestern University.
As co-founder of Carbon, DeSimone took on 3D printing by bringing together insights from diverse fields to co-invent the core technology that now drives the Carbon Platform. Powered by Digital Light Synthesis™ (DLS™) technology, the Carbon Platform is enabling companies to break free of traditional polymer manufacturing methods to advance product innovation. Just this week, he was recognized for his achievements by EY as the U.S. Entrepreneur of the Year.
Before founding Carbon in 2013, DeSimone was a professor at the University of North Carolina for over 20 years. DeSimone has made scientific breakthroughs in areas including green chemistry, medical devices, and nanotechnology, also co-founding several companies based on his research. At UNC, DeSimone built a strong culture in his research group centered on the notion that diversity is a fundamental tenet of innovation.
DeSimone has achieved international recognition as a scientist, inventor, and entrepreneur, earning major accolades including the U.S. Presidential Green Chemistry Challenge Award and the Lemelson-MIT Prize. In 2016, President Obama awarded DeSimone the National Medal of Technology and Innovation, the highest honor in the U.S. for achievement and leadership in advancing technological progress. He is also one of only roughly 20 individuals elected to all three U.S. National Academies—the National Academy of Sciences, the National Academy of Medicine, and the National Academy of Engineering.
About Carbon
Carbon’s mission is to reinvent how polymer products are designed, engineered, manufactured, and delivered towards a digital and sustainable future. Based in Silicon Valley, Carbon brings together innovations in software, hardware, and material science to deliver industry-leading digital manufacturing solutions. With Carbon’s ground-breaking Digital Light Synthesis™ technology and broad family of programmable liquid resins, manufacturers can unlock new business opportunities such as mass customization, on-demand inventory, and previously impossible product designs. The Carbon Platform allows customers to build uniquely differentiated products while reducing waste and time to market. To learn more, visit www.Carbon3d.com, like the Carbon Facebook page, or follow Carbon on Instagram and Twitter at @Carbon.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191121005835/en/
Contact information
Iska Hain Saric, Head of Strategic Communications, pr@carbon3d.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
